Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Search

Total 5 results found. Search for [ Ogivri ]

Results 1 to 5 of 5
PB Jayakumar
New Delhi, January 9, 2019
Ogivri is the biosimilar version of Swiss drug maker Roches Herceptin, a breast cancer and gastric cancer drug with sales of $6.9 billion a year worldwide


PB Jayakumar
December 19, 2018
Ogivri (Trastuzumab), jointly developed by Biocon and Mylan, is the biosimilar version of Swiss drug maker Roche's Herceptin.


PTI
December 19, 2018



E Kumar Sharma
New Delhi, October 25, 2018
Kiran Mazumdar-Shaw said Biocon delivered a strong revenue growth of 35 per cent this quarter, driven by robust performance across our biologics, small molecules and research services segments.


PTI
December 2, 2017
Ogivri is the first United States Food and Drug Administration (USFDA) approved biosimilar to Herceptin and the first biosimilar from Mylan and Biocon's joint portfolio approved in the US, the two companies said in a joint statement.


PAGES 1 OF 1